|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 231.7 USD | -0.92% |
|
+2.78% | -10.46% |
| 06-13 | REGENXBIO Inc. Announces Chief Executive Officer Changes | CI |
| 06-12 | Biogen executive plays down looming competition for its Alzheimer's drug | RE |
(Reuters) - Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for $1.15 billion in upfront and up to $650 million in potential milestone payments.
(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 231.7 USD | -0.92% | +2.78% | 33.73B | ||
| 0.34 HKD | -2.86% | -21.84% | 472M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -10.46% | 33.73B | |
| +0.85% | 92.38B | |
| -3.03% | 37.9B | |
| +74.71% | 27.98B | |
| -13.39% | 15.86B | |
| -1.08% | 13.97B | |
| -11.15% | 11.67B | |
| +169.04% | 10.17B | |
| -50.19% | 10.04B | |
| +1.12% | 8.71B |
BIOGEN INC. 
